Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
| Autor: | M. Constenla, T. Skacel, M. Clemens, P. Fargeot, R. Mahlberg, W. Brugger, V. Easton, G. Romieu, M. Schütte, P. Bacon |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Neutropenia Filgrastim Cyclophosphamide Premedication Breast Neoplasms Opportunistic Infections Polyethylene Glycols Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Aged Epirubicin Leukopenia business.industry Hematology medicine.disease Recombinant Proteins Surgery Regimen Treatment Outcome Oncology Female Fluorouracil medicine.symptom business Pegfilgrastim medicine.drug |
| Zdroj: | Critical Reviews in Oncology/Hematology. 64:64-72 |
| ISSN: | 1040-8428 |
| Popis: | This randomized phase 2 study explored the feasibility of delivering four to six cycles of the dose-intensified regimen FEC-100 (5-fluorouracil, epirubicin, and cyclophosphamide) to elderly patients with stage II-III breast cancer, using pegfilgrastim for neutrophil support. Sixty patients aged 65-77 years received single 6mg doses of pegfilgrastim on day 2 of FEC-100, either as primary prophylaxis (all cycles: PP), or as secondary prophylaxis (all cycles following a neutropenic event: SP). Neutropenic events (a composite endpoint that included grade 3 neutropenia+fever, grade 4 neutropenia, infectious complication requiring systemic anti-infectives and chemotherapy dose delay/reduction) occurred in 24/30 (80%) of the PP and 21/29 (72%) of the SP group in the first cycle. Most patients received all chemotherapy cycles at full dose on schedule (26/30 [87%] PP; 20/29 [69%] SP). These data indicate that delivery of FEC-100 is feasible with pegfilgrastim support in elderly breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect